Document is current
Any future updates will be listed below
-
Authors
Ali, Farwa https://orcid.org/0000-0001-6060-3995
Syrjanen, Jeremy A.
Figdore, Dan J. https://orcid.org/0000-0002-4776-3203
Kremers, Walter K.
Mielke, Michelle M. https://orcid.org/0000-0001-7177-1185
Jack, Clifford R. https://orcid.org/0000-0001-7916-622X
Knopman, David S. https://orcid.org/0000-0002-6544-066X
Vemuri, Prashanthi https://orcid.org/0000-0003-4286-0589
Graff-Radford, Jonathan
Windham, B. Gwen
Barnard, Leland R.
Petersen, Ronald C. https://orcid.org/0000-0002-8178-6601
Algeciras-Schimnich, Alicia
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (K23-NS124688)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U01AG006786)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (RF1-AG069052)
Tianqiao and Chrissy Chen institute. Early Career Award.
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 17 December 2024
First Online: 16 January 2025
Competing interests
: Authors declare the following competing interests: Farwa Ali receives funding from the NIH. Walter K. Kremers receives research funding from NIH, Astra Zeneca, Biogen, and Roche. Michelle M. Mielke receives research support from the NIH and DOD and has consulted for Biogen, Brain Protection Company, LabCorp, Lilly, Merck, Roche, Siemens Healthineers, and Sunbird Bio. Clifford R. Jack receives no personal compensation from any commercial entity. He receives research support from NIH, the GHR Foundation, and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic. David S. Knopman serves on a data safety monitoring board for the Dominantly Inherited Alzheimer Network TREATMENT UNIT (DIAN-TU) study and was an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. Prashanthi Vemuri receives research support from the NIH. Jonathan Graff-Radford receives funding from the NIH. He is an investigator in clinical trials sponsored by Biogen, Eisai, and the University of Southern California. He serves on the DSMB for NINDS StrokeNET. B. Gwen Windham receives funding from the NIH. Ronald C. Petersen has consulted for Roche, Inc.; Genentech, Inc.; Eli Lilly, Inc.; Nestle, Inc. and Eisai, Inc.; a DSMB for Genentech, Inc. and receives royalties from Oxford University Press for Mild Cognitive Impairment and from UpToDate. His research funding is from NIH/NIA. Alicia Algeciras-Schimnich has participated in advisory boards for Roche Diagnostics, Fujirebio Diagnostics, and Siemens Healthineers. Jeremy A. Syrjanen, Dan J. Figdore, and Leland R. Barnard report no disclosures.
